search
Back to results

Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis

Primary Purpose

Osteoarthrosis

Status
Completed
Phase
Phase 3
Locations
Brazil
Study Type
Interventional
Intervention
EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)
EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)
Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)
Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)
Sponsored by
Azidus Brasil
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthrosis

Eligibility Criteria

30 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients who agree with all aspects of the study and sign the Informed Consent;
  • Patients of both sexes;
  • Age above 30 years;
  • Clinical and radiological diagnosis of osteoarthritis;
  • Osteoarthritis in grades 1-2;
  • Patients who are conducting medical treatment and that, for trial of Investigator, is eligible for the study.

Exclusion Criteria:

  • Patients with a history of trauma clinically significant;
  • Patients who underwent surgery on joints affected;
  • Coexistence of diseases that might impede the successful conclusion of the trial (rheumatism and others);
  • Pregnant patients and / or breastfeeding;
  • Patients with phenylketonuria;
  • Patients with clinical diagnosis of severe renal failure;
  • Patients with clinical diagnosis of severe liver disease;
  • Patients with clinical diagnosis of clotting disorders;
  • Patients who are being treated with anti-aggregating and / or anticoagulants;
  • Patients with sensitive components of the formula;
  • Patients with emotional disorders that interfere with the capture of data;
  • Patients who do not agree with the purposes of the study and did not sign the Informed Consent.

Sites / Locations

  • Lal Clinica Pesquisa E Desenvolvimento Ltda

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Active Comparator

Active Comparator

Arm Label

Test 1

Test 2

Comparator 1

Comparator 2

Arm Description

Oral Powder EMS

Hard Capsules EMS

Oral Powder Zodiac

Hard capsules - Zodiac

Outcomes

Primary Outcome Measures

Decrease in pain.

Secondary Outcome Measures

Full Information

First Posted
November 26, 2008
Last Updated
February 22, 2013
Sponsor
Azidus Brasil
search

1. Study Identification

Unique Protocol Identification Number
NCT00860873
Brief Title
Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis
Official Title
Randomized Study of Two Dosage Forms (Oral Powder and Capsule) of "Chondroitin + Glucosamine Sulfate" Produced by the Laboratory EMS When Compared to the Product Condroflex (Oral Powder and Capsules) Produced by Laboratory Zodiac in the Treatment of Osteoarthrosis.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2013
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
November 2009 (Actual)
Study Completion Date
November 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Azidus Brasil

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study objective is to check the non-inferiority of the 2 formulations produced by EMS when compared with the same substances and pharmaceuticals forms of the product Condroflex (Zodiac), by promoting the relief of osteoarthrosis symptoms such as pain, stiffness and functional capacity that will be periodically measured by using the "Visual Analog Scale" of pain (VAS) and the questionnaire of Lequesne.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthrosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
280 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Test 1
Arm Type
Experimental
Arm Description
Oral Powder EMS
Arm Title
Test 2
Arm Type
Experimental
Arm Description
Hard Capsules EMS
Arm Title
Comparator 1
Arm Type
Active Comparator
Arm Description
Oral Powder Zodiac
Arm Title
Comparator 2
Arm Type
Active Comparator
Arm Description
Hard capsules - Zodiac
Intervention Type
Dietary Supplement
Intervention Name(s)
EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)
Intervention Description
Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
Intervention Type
Dietary Supplement
Intervention Name(s)
EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)
Intervention Description
Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
Intervention Type
Dietary Supplement
Intervention Name(s)
Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)
Intervention Description
Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
Intervention Type
Dietary Supplement
Intervention Name(s)
Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)
Intervention Description
Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
Primary Outcome Measure Information:
Title
Decrease in pain.
Time Frame
V0 (Screening); V1 (Inclusion); V2 (2 weeks); V3 (4 weeks); V4 (8 weeks); V5 (12 weeks); V6 (24 weeks).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients who agree with all aspects of the study and sign the Informed Consent; Patients of both sexes; Age above 30 years; Clinical and radiological diagnosis of osteoarthritis; Osteoarthritis in grades 1-2; Patients who are conducting medical treatment and that, for trial of Investigator, is eligible for the study. Exclusion Criteria: Patients with a history of trauma clinically significant; Patients who underwent surgery on joints affected; Coexistence of diseases that might impede the successful conclusion of the trial (rheumatism and others); Pregnant patients and / or breastfeeding; Patients with phenylketonuria; Patients with clinical diagnosis of severe renal failure; Patients with clinical diagnosis of severe liver disease; Patients with clinical diagnosis of clotting disorders; Patients who are being treated with anti-aggregating and / or anticoagulants; Patients with sensitive components of the formula; Patients with emotional disorders that interfere with the capture of data; Patients who do not agree with the purposes of the study and did not sign the Informed Consent.
Facility Information:
Facility Name
Lal Clinica Pesquisa E Desenvolvimento Ltda
City
Valinhos
State/Province
Sao Paulo
ZIP/Postal Code
13270000
Country
Brazil

12. IPD Sharing Statement

Learn more about this trial

Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis

We'll reach out to this number within 24 hrs